TY - JOUR
T1 - Hair loss after drug reaction with eosinophilia and systemic symptoms (DRESS)
T2 - A multicentric retrospective case series
AU - Lee, Ji Won
AU - Yu, Da Ae
AU - Cho, Soyun
AU - Youn, Sang Woong
AU - Kwon, Ohsang
N1 - Publisher Copyright:
© 2023 Japanese Dermatological Association.
PY - 2023/6
Y1 - 2023/6
N2 - Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous drug adverse reaction characterized by various cutaneous and systemic manifestations. However, reports on the various patterns of alopecia after DRESS are lacking. Thus, we aimed to describe cases of alopecia after DRESS and review the literature. This multicentric retrospective study reviewed the records of 182 patients diagnosed with DRESS from 2009 to 2021; of these, 10 who had alopecia after DRESS were included. Patients were diagnosed with permanent alopecia (n = 4), telogen effluvium (n = 5), and alopecia areata (n = 1), and were treated with topical minoxidil or alfatradiol (6; 60%), topical corticosteroids (3; 30%), dietary supplements (6; 60%), systemic corticosteroids (1; 10%), and intralesional corticosteroid injection (2; 20%). Although patients with permanent alopecia did not show hair regrowth after 6 months, those with telogen effluvium and alopecia areata experienced marked clinical improvement within 6 months. Various types of alopecia can persist over an extended period, even after the resolution of an acute episode of DRESS.
AB - Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous drug adverse reaction characterized by various cutaneous and systemic manifestations. However, reports on the various patterns of alopecia after DRESS are lacking. Thus, we aimed to describe cases of alopecia after DRESS and review the literature. This multicentric retrospective study reviewed the records of 182 patients diagnosed with DRESS from 2009 to 2021; of these, 10 who had alopecia after DRESS were included. Patients were diagnosed with permanent alopecia (n = 4), telogen effluvium (n = 5), and alopecia areata (n = 1), and were treated with topical minoxidil or alfatradiol (6; 60%), topical corticosteroids (3; 30%), dietary supplements (6; 60%), systemic corticosteroids (1; 10%), and intralesional corticosteroid injection (2; 20%). Although patients with permanent alopecia did not show hair regrowth after 6 months, those with telogen effluvium and alopecia areata experienced marked clinical improvement within 6 months. Various types of alopecia can persist over an extended period, even after the resolution of an acute episode of DRESS.
KW - alopecia
KW - alopecia areata
KW - drug eruptions
KW - drug hypersensitivity syndrome
KW - drug-related side effects and adverse reactions
UR - https://www.scopus.com/pages/publications/85146450293
U2 - 10.1111/1346-8138.16715
DO - 10.1111/1346-8138.16715
M3 - Article
C2 - 36651019
AN - SCOPUS:85146450293
SN - 0385-2407
VL - 50
SP - 814
EP - 819
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 6
ER -